FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website www.fitscreening.eu/patients

 

 

Please select your country. This will keep you up to date with your country-specific information.

  • Free Live webinar:
Before and during therapy: Optimising mCRC management
with OncoBEAM® RAS liquid biopsy
    March 7th, 05:00 PM CET
    Free Live webinar:
    Before and during therapy: Optimising mCRC management
    with OncoBEAM® RAS liquid biopsy


Confident your mCRC patient is eligible for anti-EGFR therapy?

 

Key highlights:

  • How liquid biopsy is overcoming the limitations of tissue biopsy
  • Why a highly sensitive technology is crucial for effective RAS mutation analysis
  • How liquid biopsy can improve current treatment strategies for mCRC

 

Date: March, 7th, 05:00 PM CET 

Add to calendar

Join webinar here

Meet the expert

 

“Determining RAS in serial liquid biopsies lets you monitor the clonal dynamics of tumours, detect the emergence of resistance early on, and select the right treatment at all times.”

Dr. Clara Montagut, Oncologist, Hospital del Mar, Barcelona, Spain

 

 

Dr Montagut is Head of the Gastrointestinal Cancer Section at the Medical Oncology Department of Hospital del Mar in Barcelona, and is currently working at Memorial Sloan Kettering Cancer Center in New York. She has significant experience in studies with biomarkers and liquid biopsy, including RAS ctDNA OncoBEAM testing for diagnosing and monitoring colorectal cancer patients.